US 12,296,053 B2
Nanomaterials comprising triols
Cory Dane Sago, Cambridge, MA (US); Gregory Lawrence Hamilton, Cambridge, MA (US); and Neeraj Narendra Patwardhan, Cambridge, MA (US)
Assigned to Beam Therapeutics Inc., Cambridge, MA (US)
Filed by Beam Therapeutics Inc., Cambridge, MA (US)
Filed on Mar. 20, 2024, as Appl. No. 18/611,561.
Application 18/611,561 is a continuation of application No. PCT/US2023/027741, filed on Jul. 14, 2023.
Claims priority of provisional application 63/390,882, filed on Jul. 20, 2022.
Prior Publication US 2024/0252443 A1, Aug. 1, 2024
Int. Cl. A61K 9/50 (2006.01); A61K 39/385 (2006.01); A61K 48/00 (2006.01); C07C 271/20 (2006.01); C07D 295/13 (2006.01); C12N 15/113 (2010.01)
CPC A61K 9/5015 (2013.01) [A61K 39/385 (2013.01); A61K 48/0033 (2013.01); C07C 271/20 (2013.01); C07D 295/13 (2013.01); C12N 15/113 (2013.01)] 26 Claims
 
1. A compound of Formula IX-B-i:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
each L2 and L2′ is independently a bivalent saturated, straight or branched C1-12 hydrocarbon chain;
R1 is optionally substituted C1-20 aliphatic;
each R1′ is independently optionally substituted C1-20 aliphatic;
Y2 is a bivalent saturated, straight or branched C1-6 hydrocarbon chain;
Y3 is optionally substituted C1-20 aliphatic; and
—X2-X3 is

OG Complex Work Unit Chemistry